European Economic News Preview: UK Unemployment Data Due
https://www.rttnews.com/3410860/european-economic-news-preview-uk-unemployment-data-due.aspx?type=alleco
Dec 11, 2023 - Unemployment from the UK and economic sentiment from Germany are the major economic reports due on Tuesday, headlining a light day for the European economic news. At 2.00 am ET, the Office for National Statistics releases UK unemployment data for October. The jobless rate is forecast to remain unchanged at 4.2 percent in three months to October.
0
Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript)
https://seekingalpha.com/article/4657329-editas-medicine-inc-edit-editminus-301-program-update-ruby-and-edithal-trials-data-update?source=feed_sector_transcripts
Dec 11, 2023 - Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ETCompany...
0
Japan Producer Price Data Due On Tuesday
https://www.rttnews.com/3410549/japan-producer-price-data-due-on-tuesday.aspx?type=alleco
Dec 11, 2023 - Japan will on Tuesday release November numbers for producer prices, highlighting a light day for Asia-Pacific economic activity.
0
MorphoSys climbs after late-stage data for blood cancer therapy
https://seekingalpha.com/news/4045175-morphosys-stock-climbs-data-blood-cancer-therapy?source=feed_sector_healthcare
Dec 11, 2023 - MorphoSys (MOR) shares surge 22% as Phase 3 results show promising outcomes for pelabresib in treating a rare bone marrow cancer called myelofibrosis. Read more here.
0
Keros falls after mid-stage data for blood cancer therapy
https://seekingalpha.com/news/4045165-keros-stock-falls-after-mid-stage-data-blood-cancer-drug?source=feed_sector_healthcare
Dec 11, 2023 - Keros Therapeutics (KROS) stocks fell 16% after updating data from two Phase 2 trials for its lead protein drug in rare forms of blood cancer. Read more here.
0
Syndax reports encouraging Phase 1 data for leukemia drug
https://seekingalpha.com/news/4045154-syndax-reports-encouraging-phase-1-data-for-leukemia-drug?source=feed_sector_healthcare
Dec 11, 2023 - Syndax (SNDX) shares gained ground Monday after the company reported positive Phase 1 data for its drug revumenib in the treatment of acute leukemias. Read more here.
0
Pasithea stock soars as high as 190% on preclinical data
https://seekingalpha.com/news/4045130-pasithea-stock-soars-on-preclinical-data?source=feed_sector_healthcare
Dec 11, 2023 - Pasithea (KTTA) shares soared as high as 190% after the company released encouraging data from two preclinical studies of its oncology drug candidate PAS-004. Read more here.
0
Big Week for Fed FOMC and Key Inflation Data
https://www.zacks.com/stock/news/2196251/big-week-for-fed-fomc-and-key-inflation-data?cid=CS-ZC-FT-economic_highlights-2196251
Dec 11, 2023 - Big Week for Fed FOMC and Key Inflation Data.
0
Economic Data Raises Hope for Soft Landing: 5 Top Picks
https://www.zacks.com/stock/news/2195993/economic-data-raises-hope-for-soft-landing-5-top-picks?cid=CS-ZC-FT-analyst_blog|investment_ideas-2195993
Dec 11, 2023 - We have narrowed our search to five large-cap stocks that have strong potential for 2024. These are: IT, INTC, RCL, EMR, PGR.
0
Japan Money Stock Data Due On Monday
https://www.rttnews.com/3410535/japan-money-stock-data-due-on-monday.aspx?type=alleco
Dec 10, 2023 - Japan will on Monday release November numbers for money stock, highlighting a light day for Asia-Pacific economic activity. The M2 money stock is expected to rise 2.5 percent on year, up from 2.4 percent in October.
0